Evaluation of miR-302c-3p as prognostic biomarkers in glioma patients.
This study aimed to explore the clinicopathological and prognostic significance of miR-302c-3p in glioma. The expression of miR-302c-3p in glioma tissues and normal brain tissues was measured using real-time PCR. Clinicopathological associations of miR-302c-3p expression in glioma were analyzed. The Kaplan-Meier method was used to determine the survival curves. Univariate and multivariate analysis were performed using the Cox proportional hazard analysis. The relative expression of miR-302c-3p in glioma tissues was significantly lower than that in non-neoplastic brain tissues (p < 0.001). The decreased expression of miR-302c-3p in glioma was positively associated with WHO grade (p < 0.001) and Karnofsky performance status (KPS) score (p = 0.016). We found patients with low miR-302c-3p expression had significantly poorer OS (p = 0.0057) and PFS (p = 0.0092) by Kaplan-Meier method. Furthermore, multivariate regression analysis identified low miR-302c-3p expression as an independent predictor of poor survival. Our results revealed that miR-302c-3p may serve as a tumor suppressor of malignant glioma and be used as a novel biomarker to predict the clinical prognostic of patients with gliomas.